telehealth.helpFind my match

Home WikiTelehealth Concepts

GIP (glucose-dependent insulinotropic polypeptide)

From WikiTelehealth, the telehealth.help reference · Last updated

GIP (glucose-dependent insulinotropic polypeptide) is a hormone released by the upper small intestine after a meal that helps the pancreas release insulin. It is one of the two main incretin hormones, along with GLP-1, and is a drug target in tirzepatide and retatrutide.

GIP (glucose-dependent insulinotropic polypeptide)
TypePeptide hormone (incretin)
Length42 amino acids
Made byK cells of the duodenum and jejunum
DescribedEarly 1970s
Original nameGastric inhibitory polypeptide
Drugs that target itTirzepatide (approved), retatrutide (investigational)

History

GIP was found by John Brown and colleagues in Canada around 1970 while they searched for gut factors that reduce stomach acid. They named it gastric inhibitory polypeptide. In 1973, a study in people showed that GIP raises insulin release when blood sugar is up. The name was later changed to glucose-dependent insulinotropic polypeptide, which kept the same letters.

GIP was the first incretin to be described. GLP-1 was identified more than 10 years later. For decades, GIP drew less attention because it had a weak effect on blood sugar in people with type 2 diabetes.

Physiology

GIP is made by K cells in the first part of the small intestine. Together with GLP-1, it accounts for the incretin effect: the finding that sugar taken by mouth causes more insulin release than the same sugar given into a vein. GIP receptors are also found in fat tissue and the brain, and researchers are still studying what GIP does there.

GIP is released mainly in response to fat and sugar in a meal. In people with type 2 diabetes, the pancreas responds much less to GIP than normal, while its response to GLP-1 is better kept. This is one reason early drug makers focused on GLP-1 alone.

As a drug target

Tirzepatide was the first approved medicine to activate both the GIP and GLP-1 receptors. The FDA approved it as Mounjaro for type 2 diabetes on May 13, 2022 and as Zepbound for chronic weight management on November 8, 2023. Its labels describe it as a GIP receptor and GLP-1 receptor agonist.

In the one head-to-head trial, SURMOUNT-5, people on tirzepatide lost 20.2% and people on semaglutide lost 13.7% after 72 weeks (treatment-regimen estimand). Researchers think the GIP action may add to weight loss and may ease nausea, but how much each receptor contributes is still debated.

Retatrutide, an investigational medicine, acts on GIP, GLP-1 and glucagon receptors. Our semaglutide vs. tirzepatide guide compares the GLP-1-only and dual approaches in more detail.

Blocking GIP

Scientists still debate whether turning the GIP receptor on or off is better for weight loss, because animal and genetic studies have pointed both ways. Amgen's investigational medicine maridebart cafraglutide takes the opposite approach to tirzepatide: it activates the GLP-1 receptor and blocks the GIP receptor. It is a monthly injection being tested in a phase 3 program called MARITIME and is not approved.

Compare semaglutide and tirzepatide

See also

References

  1. Physiology, Gastric Inhibitory Peptide, StatPearls (NCBI Bookshelf). pubmed.ncbi.nlm.nih.gov
  2. Mounjaro prescribing information, DailyMed. dailymed.nlm.nih.gov
  3. FDA approves new medication for chronic weight management (FDA, November 8, 2023). fda.gov
  4. Aronne et al., NEJM 2025 (SURMOUNT-5). pubmed.ncbi.nlm.nih.gov
  5. Jastreboff et al., NEJM 2023 (retatrutide phase 2). pubmed.ncbi.nlm.nih.gov
  6. MARITIME-1 study record, NCT06858839, ClinicalTrials.gov. clinicaltrials.gov

Last updated . Category: Concepts. Browse all 38 WikiTelehealth entries.